Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "CDMO"

269 News Found

Strides secures shareholders approval for OneSource CDMO
News | September 12, 2024

Strides secures shareholders approval for OneSource CDMO

The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE


AGC and Medinet sign agreement for cell therapy CDMO business
News | September 12, 2024

AGC and Medinet sign agreement for cell therapy CDMO business

A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan


Akums appoints Amrut Medhekar as CEO - CDMO Business
People | August 26, 2024

Akums appoints Amrut Medhekar as CEO - CDMO Business

e brings over 27+ years of rich pharmaceutical experience


Lupin appoints Abdelaziz Toumi as CEO of its API CDMO subsidiary
People | June 17, 2024

Lupin appoints Abdelaziz Toumi as CEO of its API CDMO subsidiary

Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,


Suven to acquire a majority stake in CDMO player ‘Sapala Organics’
News | June 14, 2024

Suven to acquire a majority stake in CDMO player ‘Sapala Organics’

Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies


Grace expands CDMO capacity by 25% of South Haven facility in Michigan
News | March 19, 2024

Grace expands CDMO capacity by 25% of South Haven facility in Michigan

Additional capacity broadens Grace’s fine chemical capabilities for API production


Bajaj Healthcare enters into definitive CDMO Agreement for 15 APIs with UK/EU customers
News | February 29, 2024

Bajaj Healthcare enters into definitive CDMO Agreement for 15 APIs with UK/EU customers

BHL will undertake the development and supply of these molecules


Glenmark Life Sciences inks CDMO supply deal with a Japanese pharma innovator
News | January 19, 2024

Glenmark Life Sciences inks CDMO supply deal with a Japanese pharma innovator

Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator


AGC invests US$ 348 million to expand its biopharmaceutical CDMO capability
News | December 21, 2023

AGC invests US$ 348 million to expand its biopharmaceutical CDMO capability

Development services for gene and cell therapies is planned to begin first in 2025